SA-hirudin-RGD融合蛋白的原核表达及其抗凝血酶与抗血小板聚集功能的研究

目的:构建SA-hirudin-RGD重组载体,表达和纯化融合蛋白,并对其抗凝血酶、抗血小板聚集功能进行初步验证。方法:利用基因重组技术将链霉亲和素(SA)核心区与hirudin-RGD序列连接,并克隆到原核表达载体PET-44b中,Westernblotting鉴定经IPTG诱导后纯化的融合蛋白。抗凝血酶和抗血小板聚集作用分析证明该融合蛋白既有抗凝血酶又有抗血小板聚集的功能。结果:重组载体p ET44b-SA-hirudin-RGD经限制性酶切鉴定和基因测序证实构建成功;经IPTG诱导后SA-hirudin-RGD融合蛋白在大肠杆菌中高效表达;纯化得到该目的蛋白,相对分子质量经Westernblotting鉴定约为70000。抗凝血酶和抗血小板聚集的实验证明,融合蛋白SA-hirudin-RGD既有抗凝血酶又有抗血小板聚集的功能。结论:具有抗凝血酶和抗血小板聚集双重功能的SA-hirudin-RGD融合蛋白被成功表达和纯化,为下一步SA-hirudin-RGD的功能研究及临床应用确立了基础。     

水稻非特异性脂质转移蛋白的原核表达、纯化及抑菌功能

将编码水稻非特异性脂质转移蛋白 (nonspecificlipidtransferprotein ,nsLTP)基因 (LTP110 )的克隆到硫氧还蛋白融合表达载体PET32a( )中 ,在BL2 1(DE3)trxB-宿主菌中实现了融合蛋白的高表达。通过Ni2 chelatingSepharosefastflow柱纯化融合蛋白后 ,通过肠激酶酶切再过该亲和柱得到了重组LTP110。CD谱扫描表明重组蛋白质与体内提取的nsLTP二级结构相似 ;荧光脂质结合实验表明该蛋白质具有结合脂肪酸分子的活性。对该蛋白质的抑菌功能进行研究后表明 ,LTP110具有抑制稻瘟病菌孢子萌发的功能 ,在较低浓度即能发挥活性     

乙型肝炎病毒靶向核糖核酸酶及其突变体的原核表达和活性分析

目的：研究原核表达的乙型肝炎病毒（HBV）靶向核糖核酸酶（RNase）及其突变体（点突变失去RNase活性）的活性。方法：将构建的靶向核糖核酸酶及其突变体基因克隆入原核表达载体pET32a（＋），转化大肠杆菌BL21（DE3），以IPTG诱导融合蛋白（HBV核心蛋白与人嗜酸性粒细胞来源的神经毒素的融合蛋白）的表达；表达产物经包涵体纯化、SDS-PAGE和Western印迹鉴定，将纯化的蛋白用透析方法复性；以酵母tRNA为作用底物，应用复性的蛋白进行RNase活性分析。结果：纯化和复性了HBV靶向核糖核酸酶及其突变体；复性的HBV靶向核糖核酸酶可以降解酵母tRNA且具有剂量依赖性，而复性后的突变的靶向核糖核酸酶体不具有RNase活性。结论：原核表达的HBV靶向核糖核酸酶具有较强的RNase活性，为探索HBV靶向核糖核酸酶抑制乙肝病毒复制的机理奠定了基础。     

甲基对硫磷水解酶基因的高效表达及酶活性分析

假单胞菌WBC 3的甲基对硫磷水解酶基因mph在大肠杆菌系统AD494(DE3) pET32a ( + )中实现了高效可溶性融合表达。表达的重组酶能够有效地被亲合层析纯化。酶学性质分析表明 ,重组酶对底物乙基对硫磷水解能力较野生酶相比有近 4倍的提高 ,对甲基对硫磷和杀螟松的水解活力无明显变化。以融合蛋白形式存在的重组酶在室温及 4℃下的贮存稳定性明显优于野生型酶。     

枯草杆菌谷氨酰胺转胺酶的克隆及其在大肠杆菌中的融合表达

利用PCR技术 ,从枯草杆菌DB40 3染色体上扩增出谷氨酰胺转胺酶基因 ,将其克隆到大肠杆菌载体pET32a( + )中 ,成功构建谷氨酰胺转胺酶表达载体pET32-BTGase ,并转化大肠杆菌BL2 1 (DE3)。重组克隆在IPTG诱导下 ,表达出硫氧还蛋白 谷氨酰胺转胺酶 (Trx-BTGase)融合蛋白 ,表达量占细菌总蛋白量的 2 6%。利用金属螯合层析纯化菌体裂解上清中表达的融合蛋白 ,纯度超过 80 %,再通过分子筛层析进一步纯化得到融合蛋白纯品。酶活性分析表明表达的Trx-BTGase融合蛋白具有交联蛋白的活性 ,并发现Trx-BTGase融合蛋白和经凝血酶酶切后得到的BTGase单体都能催化牛血清白蛋白的聚合反应     

表达VP3重组减毒沙门氏菌的构建和融合蛋白纯化

寻求有效的肿瘤基因疗法,构建鸡贫血病毒VP3的减毒鼠伤寒沙门氏菌疫苗,并获得较纯的表达VP3基因的融合蛋白,初步研究其免疫原性.采用PCR技术扩增VP3基因,并将其与原核载体pET32α( )重组.将重组后质粒转染E.coli BL21,得到表达VP3的融合蛋白,并将此蛋白通过50%的Ni -NTA亲和树脂纯化.同时将重组质粒转染减毒沙门氏菌SL7207.经双酶切和PCR鉴定,成功构建了表达VP3的减毒沙门氏菌苗.融合蛋白通过50%的Ni -NTA亲和树脂纯化,得到纯度在90%以上的纯化蛋白.成功构建了表达VP3的减毒沙门氏菌苗,并且获得纯化的表达VP3的融合蛋白,为进一步研究VP3的免疫保护作用及对抗肿瘤疫苗的研制打下基础.     

小鼠核糖核酸酶抑制剂的高效可溶性表达与氧化抗性鉴定

核糖核酸酶抑制剂(Ribonuclease inhibitor, RI)是一种细胞内能够调节核糖核酸酶活性的胞浆蛋白,在分子生物学涉及RNA的实验中有广泛应用。商品化的小鼠RI(mRI)宣称其可能具有较高的氧化抗性。为获得mRI在大肠杆菌宿主中可溶性活性产物的有效重组表达,构建了含有mRI编码基因的重组质粒载体,在几种不同工程菌中进行了mRI蛋白的表达纯化,并观察了其氧化抗性特征。简单的组氨酸标签融合,即可在蛋白酶基因缺陷的BL21衍生的宿主菌中,经过适当诱导,获得较高水平活性产物的可溶性表达。纯化后产量在4~8mg/L水平,接近其他种属RI特殊优化表达系统的最高产量。该重组mRI与重组人RI(hRI)具有基本一致的核糖核酸酶抑制活性和抗氧化作用,与前人推测的抗氧化特征不同。     

乙肝PreS2抗原决定簇和霍乱毒素B亚基基因的融合与表达

通过全化学法按大肠杆菌密码偏性合成了乙肝炎病毒前Ｓ２抗原抗原决定簇基因,与霍乱毒素Ｂ亚基基因的３＇端融合,重组质粒转化大肠杆菌后融合基因得到高效表达,表达量达３０μｇｍＬ,表达产物９５％以上分泌到胞外,表达的融合蛋白能与神经节苷脂ＧＭ１结合,说明融合蛋白保持了霍乱霉素Ｂ亚基的基本高级结构和生物学功能;酶联免疫吸附实验证明融合蛋白具有ＣＴＢ和ＨＢＶＰｒｅＳ２的抗原性;应用亲和层析纯化后得到了电泳纯融     

宫颈癌相关BLCAP基因的原核表达及条件优化

目的利用大肠埃希菌表达系统表达宫颈癌相关BLCAP基因,并优化表达条件。方法利用PCR技术从逆转录病毒重组载体pL（BLCAP）SN中扩增宫颈癌相关BLCAP基因,将其插入到原核表达载体pET-32（a）中,从而构建原核表达重组质粒pET-32（a）-BLCAP,随后将阳性重组质粒转化到表达宿主菌中,通过IPTG诱导表达并优化表达条件,所表达的带有His标签目的融合蛋白经Ni^2＋亲和层析纯化回收,并采用SDS—PAGE和Western印迹对目的蛋白进行分析和鉴定。结果构建的重组表达质粒经PCR、酶切和DNA测序鉴定与预期的结果一致,含有重组质粒的表达宿主菌经过IPTG诱导表达了分子量约为28ku的融合蛋白,并经优化确定了最佳的诱导表达条件。结论成功构建了pET-32（a）-BLCAP原核表达质粒,表达并经纯化得到了BLCAP目的蛋白,为研究该蛋白的性质及其制备针对该蛋白的抗体奠定了基础。     

PSCA-HSP70融合蛋白在大肠杆菌中的表达与纯化

旨在大肠杆菌中表达PSCA-HSPT0融合蛋白,并对其进行纯化.克隆人PSCA基因及HSP70基因,构建表达PSCA-HSP融合蛋白的工程菌,优化表达及纯化条件,对重组蛋白进行纯化.结果表明,成功构建重组表达质粒PSCA-HSP,重组蛋白得到可溶性表达,优化纯化条件后获得90%以上纯度的重组蛋白.本研究成功实现了PSCA与HSP的融合表达,为下一步肿瘤疫苗的研制奠定基础.     

胆汁三烯结合蛋白在大肠杆菌中的表达、复性与纯化

目的：合成胆汁三烯结合蛋白（BBP）基因并在大肠杆菌中表达,获得重组BBP纯化制品。方法：根据天然BBP的基因序列和大肠杆菌偏好密码子设计并合成BBP基因的引物,PCR扩增优化的BBP基因序列,克隆至载体pEasy-T3;测序正确后,将该序列克隆至表达载体pET-32a上,构建表达质粒,转化至大肠杆菌BL21（DE3）pLysS,在IPTG诱导下表达融合蛋白;采用Ni柱纯化融合蛋白。结果：PCR扩增获得了优化后的BBP基因序列,构建了表达载体pET-32a-BBP;SDS-PAGE分析表明表达的融合蛋白相对分子质量为20×10^3,以包涵体形式存在,占全菌蛋白的40%以上;变性、复性后经Ni2＋柱纯化,获得纯度达98%以上的重组蛋白。结论：优化并合成了BBP全基因序列,获得了高纯度重组融合蛋白,为进一步鉴定其生物活性及筛选小分子的研究奠定了基础。     

人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白的原核表达及纯化

目的:表达和纯化人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白。方法:利用PCR搭接方法及基因合成方法获得目的基因,插入带有6×His标签的原核高效可溶性表达载体pET32a中,构建重组表达质粒pET32a-T9-ac-9,将重组表达质粒转化大肠杆菌BL21(DE3),经IPTG诱导目的基因表达;对融合蛋白进行Ni2+金属螯合柱纯化。结果:构建的重组表达质粒经PCR、内切酶鉴定及基因序列测定证实;目的蛋白在大肠杆菌中获得表达,SDS-PAGE显示相对分子质量为22.917×103;对表达产物进行了亲和层析纯化,从上清中获得了纯度较高的人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白。结论:获得了可溶性的人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白,为其生物学功能研究奠定了基础。     

日本血吸虫中国大陆株22.6kD膜相关蛋白基因的克隆及其在大肠杆菌中的高效表达

以日本血吸虫ｍＲＮＡ为模板,用ＲＴＰＣＲ法快速克隆到一大小约６００ｂｐ的ＤＮＡ片段,ＤＮＡ序列分析证实,所扩增到的ＤＮＡ片段中含有日本血吸虫２２６膜相关蛋白（Ｓｊ２２６（Ｃｈ））基因,将该基因重组到表达型质粒ｐＧＥＸ４Ｔ中,表达的ＧＳＴ融合蛋白分子量约４８ｋＤ,用谷胱甘肽琼脂糖凝胶亲和层析柱纯化的重组蛋白不仅纯度好,而且得率高,纯化产量可达４０ｍｇ／Ｌ培养物,免疫试验结果表明该重组蛋白具有良好的抗原性,为其在血吸虫病抗感染中的免疫作用研究创造了条件。     

Expression of human cardiac-specific homeobox protein in Escherichia coli

Human cardiac-specific homeobox protein cDNA (hCsx) was cloned into expression plasmid pET32a and fused with Escherichia coli thioredoxin (Trx). The Trx-Csx fusion protein was under the control of bacteriophage T7 promoter. When expressed in E. coli BL21(DE3), about half of the recombinant Trx-Csx products existed in the form of insoluble inclusion bodies. When coexpressed with human protein disulfide isomerase, more than 90% of Trx-Csx products accumulated in the soluble form in the cell lysate. The recombinant Csx fusion protein was purified by one-step metal-chelating affinity chromatography.     

Expression and purification of active recombinant platelet factor 4 from a cleavable fusion protein

A synthetic gene for human platelet factor 4 (hPF4) has been expressed at high levels as a fusion protein in Escherichia coli. The hPF4 sequence has been cleaved from the fusion protein by cyanogen bromide treatment and purified by column chromatography. Like hPF4, our recombinant hPF4 (rhPF4) is tetrameric under physiological conditions, binds heparin, and inhibits angiogenesis. Extensive purification to remove trace amounts of uncleaved fusion protein completely from the desired product rhPF4 was difficult. We have exploited recombinant DNA technology by modifying the fusion moiety to accomplish separation. This type of modification, which did not affect expression level, could be applied to other recombinant fusion proteins.     

Expression of bioactive recombinant GSLL-39, a variant of human antimicrobial peptide LL-37, in Escherichia coli

The human cationic antimicrobial peptide hCAP-18/LL-37 is the unique cathelicidin identified in human to date. It has broad spectrum of antimicrobial activities and LPS-neutralizing activity and is involved in angiogenesis. Both purified and synthetic LL-37 or its derivatives were used in the study on LL-37. However, production of LL-37 in Escherichia coli has not been established. In this study, its precursor instead of the mature peptide was adopted for expression to avoid the lethal effect of recombinant LL-37 on host cells. A thrombin recognition site was introduced between the cathelin-like domain and LL-37 domain by overlap PCR to construct fragment encoding modified precursor (mhCAP-18) to facilitate the final release of the recombinant peptide. Then mhCAP-18 was fused in-frame to thioredoxin gene under the control of inducible T7 promoter to construct expression vector pET-mhCAP-18. The soluble form fusion protein was expressed in E. coli and purified by Chelating Sepharose column chromatography. Thrombin digestion of the fusion protein yielded recombinant GSLL-39, which was then purified by cation-exchange chromatography. Recombinant GSLL-39, which has two extra residues on its N-terminus when compared with its native counterpart, showed similar antimicrobial activities against both Gram-negative and Gram-positive bacteria.     

Production of a biologically active variant form of recombinant human secretin

A biologically active variant form of recombinant human secretin was produced using a gene fusion system designed to facilitate the purification of the protein. The fusion protein was recovered from the culture medium of Escherichia coli by IgG affinity chromatography, and recombinant secretin was released by cyanogen bromide treatment. A novel approach involving addition of a C-terminal Gly-Lys-Arg extension, was used to overcome the lack of amidation of recombinant proteins in Escherichia coli. The biological activity of the recombinant variant of secretin was at least 80% of the porcine secretin standard.     

抗菌肽CM4与人可溶性B淋巴细胞因子hsBAFF在大肠杆菌中的融合表达

为进一步探讨抗菌肽CM4的原核表达及其生物学功能，本实验研究了抗菌肽CM4与人可溶性B淋巴细胞刺激因子hsBAFF的融合表达及抗菌肽CM4的生物学活性。运用PCR把B淋巴细胞因子hsBAFF和家蚕抗菌肽CM4进行基因融合，构建了融合表达载体pET28a (+)/CM4-hsBAFF，并在大肠杆菌中获得高可溶性表达的融合靶蛋白，且存在于超声破碎后的上清，经分子筛Sephadex G-75纯化后的重组融合蛋白用SDS-PAGE和Western blot分析鉴定.SDS-PAGE分析表明：可以通过分子筛一步纯化得到融合蛋白，该重组融合蛋白的分子量约22.0 KDa。Western blot结果显示该重组蛋白能与鼠抗人hsBAFF的抗体发生特异性反应.运用基因工程的方法获得CM4-hsBAFF重组融合蛋白，并具有很好的抑菌生物学活性。     

A novel method for increasing the expression level of recombinant proteins

Expression of recombinant proteins is an important step towards elucidating the functions of many genes discovered through genomic sequencing projects. It is also critical for validating gene targets and for developing effective therapies for many diseases. Here we describe a novel method to express recombinant proteins that are extremely difficult to produce otherwise. The increased protein expression level is achieved by using a fusion partner, MTB32-C, which is the carboxyl terminal fragment of the Mycobacterium tuberculosis antigen, MTB32 (Rv0125). By fusing MTB32-C to the N-termini of target genes, we have demonstrated significant enhancement of recombinant protein expression level in Escherichia coli. The inclusion of a 6xHis tag and the 128-amino acid of MTB32-C will add 13.5 kDa to the fusion molecule. Comparison of the mRNA levels of the fusion and non-fusion proteins indicated that the increased fusion protein expression may be regulated at translational or post-translational steps. There are many potential applications for the generated fusion proteins. For example, MTB32-C fusion proteins have been used successfully as immunogens to generate both polyclonal and monoclonal antibodies. These antibodies have been used to characterize cellular localization of the proteins and to validate gene targets at protein level. In addition, these antibodies may be useful in diagnostic and therapeutic applications for many diseases. If desired, the MTB32-C portion in the fusion protein can be removed after protein expression, making it possible to study protein structure and function as well as to screen for potential drugs. Thus, this novel fusion expression system has become a powerful tool for many applications.     

p16抑癌基因定点突变及其在大肠杆菌中的表达与纯化

为了研究错义突变对ｐ１６功能的影响,应用ＰＣＲ体外定点突变方法对ｐ１６ｃＤＮＡ进行体外定点突变,并将野生型和突变型ｐ１６ｃＤＮＡ克隆于ｐＧＥＸ－５Ｔ载体,在大肠杆菌中经ＩＰＴＧ诱导表达,Ｗｅｓｔｅｒｎ印迹鉴定确证表达．而后用谷胱甘肽－Ｓｅｐｈａｒｏｓｅ４Ｂ亲和层析纯化野生型和突变型ｐ１６融合蛋白．得到了第４８位密码子ＣＣＧ（Ｐｒｏ）→ＣＴＧ（Ｌｅｕ）突变的ｐ１６－Ｐ４８突变体,并在大肠杆菌中表达了４２ｋＤ的ＧＳＴ－ｐ１６和ＧＳＴ－ｐ１６Ｐ４８Ｌ融合蛋白．最后经纯化得到了野生和Ｐ４８Ｌ突变的ｐ１６融合蛋白